CDK5 in oncology: recent advances and future prospects

被引：33

作者：

Lenjisa, Jimma Likisa ^{[1
]}

Tadesse, Solomon ^{[1
]}

Khair, Nishat Zareen ^{[1
]}

Kumarasiri, Malika ^{[1
]}

Yu, Mingfeng ^{[1
]}

Albrecht, Hugo ^{[1
]}

Milne, Robert ^{[1
]}

Wang, Shudong ^{[1
]}

机构：

[1] Univ South Australia, Ctr Drug Discovery & Dev, Sansom Inst Hlth Res, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia

来源：

FUTURE MEDICINAL CHEMISTRY | 2017年 / 9卷 / 16期

关键词：

cancer; cancer hallmarks; CDK; CDK5; inhibitors; p25; p35; targeted cancer therapy; CYCLIN-DEPENDENT KINASE-5; LUNG-CANCER CELLS; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA; BIOLOGICAL EVALUATION; INHIBITOR DINACICLIB; POTENTIAL TREATMENT; REGULATORY PROTEIN; TUMOR ANGIOGENESIS; ANDROGEN RECEPTOR;

D O I：

10.4155/fmc-2017-0097

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Selective abrogation of cyclin-dependent kinases (CDK) activity is a highly promising strategy in cancer treatment. The atypical CDK, CDK5 has long been known for its role in neurodegenerative diseases, and is becoming an attractive drug target for cancer therapy. Myriads of recent studies have uncovered that aberrant expression of CDK5 contributes to the oncogenic initiation and progression of multiple solid and hematological malignancies. CDK5 is also implicated in the regulation of cancer stem cell biology. In this review, we present the current state of knowledge of CDK5 as a druggable target for cancer treatment. We also provide a detailed outlook of designing selective and potent inhibitors of this enzyme.

引用

页码：1939 / 1962

页数：24

共 50 条

[21] Metabolomics: Recent Advances and Future Prospects Unveiled
Sharma, Shweta
Singh, Garima
Akhter, Mymoona
CURRENT BIOINFORMATICS, 2024, 19 (07) : 601 - 611
[22] Recent advances in diagnosis of HIV and future prospects
Arya, Swati
Lal, Pooja
Singh, Pamela
Kumar, Ashok
INDIAN JOURNAL OF BIOTECHNOLOGY, 2015, 14 (01): : 9 - 18
[23] Personalized oncology: Recent advances and future challenges
Kalia, Madhu
METABOLISM-CLINICAL AND EXPERIMENTAL, 2013, 62 (01): : S11 - S14
[24] Epidemiology of sarcoidosis: Recent advances and future prospects
Rybicki, Benjamin A.
Iannuzzi, Michael C.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 28 (01) : 22 - 35
[25] PHOSPHORYLATION OF CDK5 AT TYR15 IS INHIBITED BY P35 CDK5 ACTIVATOR AND DOES NOT CONTRIBUTE TO THE ACTIVATION OF CDK5
Kobayashi, H.
Saito, T.
Sato, K.
Minegishi, S.
Hisanaga, S.
JOURNAL OF NEUROCHEMISTRY, 2011, 118 : 74 - 75
[26] Src binds directly to Cdk5 without requirement for Cdk5 activity or phosphorylation
Zelenka, PS
Qiao, F
Gao, CY
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
[27] Identification of a neuronal Cdk5 activator-binding protein as Cdk5 inhibitor
Ching, YP
Pang, ASH
Lam, WH
Qi, RZ
Wang, JH
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (18) : 15237 - 15240
[28] An unusual member of the Cdk family: Cdk5
Dhariwala, Fatema A.
Rajadhyaksha, Medha S.
CELLULAR AND MOLECULAR NEUROBIOLOGY, 2008, 28 (03) : 351 - 369
[29] An Unusual Member of the Cdk Family: Cdk5
Fatema A. Dhariwala
Medha S. Rajadhyaksha
Cellular and Molecular Neurobiology, 2008, 28 : 351 - 369
[30] Fyn tyrosine kinase activates Cdk5 by stabilizing Cdk5 activator p35 but not phosphorylation of Cdk5 at Tyr15
Kobayashi, H.
Saito, T.
Furusawa, K.
Asada, A.
Hisanaga, S.
JOURNAL OF NEUROCHEMISTRY, 2014, 130 : 46 - 46

← 1 2 3 4 5 →